Celon Pharma SA (CLN) — Capital Reinvestment Ratio

Latest as of December 2025: 0.72x

Celon Pharma SA (CLN) has a Capital Reinvestment Ratio of 0.72x as of December 2025, meaning it reinvests 1% of its operating cash flow (zł36.63 Million) in capital expenditures (zł26.48 Million). Check tangible net worth ratio of Celon Pharma SA to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.72x
Capex / Operating Cash Flow

Operating Cash Flow

zł36.63 Million
PLN

Capital Expenditures

zł26.48 Million
PLN

Data as of

Dec 2025
Most recent filing

Celon Pharma SA Capital Reinvestment Ratio (2012–2025)

This chart tracks Celon Pharma SA's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Celon Pharma SA cash conversion from operations.

Annual Capital Reinvestment Ratio for Celon Pharma SA (2012–2025)

Year-by-year Capital Reinvestment Ratio for Celon Pharma SA from 2012 to 2025. See CLN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (PLN) Capital Expenditures YoY Change
2025 2.28x zł23.86 Million zł54.44 Million ▲ +142.4%
2021 0.94x zł43.95 Million zł41.35 Million ▼ -32.7%
2020 1.40x zł70.90 Million zł99.16 Million ▼ -41.5%
2018 2.39x zł28.24 Million zł67.46 Million ▲ +92.9%
2017 1.24x zł25.30 Million zł31.34 Million ▲ +20.1%
2016 1.03x zł20.65 Million zł21.29 Million ▲ +20.4%
2015 0.86x zł52.37 Million zł44.86 Million ▼ -7.5%
2014 0.93x zł24.36 Million zł22.55 Million ▲ +38.6%
2013 0.67x zł8.45 Million zł5.64 Million ▲ +97.8%
2012 0.34x zł12.87 Million zł4.34 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow